Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1NET 1Gynecologic 1Genitourinary 1Gastrointestinal 1Endocrine 1Breast 1

Conditions

Carcinoma, Renal Cell 3Prostatic Neoplasms 2Bile Duct Neoplasms 2Vulvar Neoplasms 1Sarcoma 1Ovarian Neoplasms 1Neuroendocrine Tumors 1Neoplasm Metastasis 1Hereditary Sensory and Autonomic Neuropathies 1Gallbladder Neoplasms 1Disease Progression 1Cholangiocarcinoma 1Carcinoma, Neuroendocrine 1Breast Neoplasms 1

Interventions

pembrolizumab 3lenvatinib 2Specimen Handling 2Nivolumab 2Cisplatin 2trastuzumab deruxtecan 1tivozanib 1liposomal doxorubicin 1entinostat 1dostarlimab 1bintrafusp alfa protein, human 1atezolizumab 1Therapeutic Touch 1Surveys and Questionnaires 1Radiotherapy 1Radiation 1Platinum 1Paclitaxel 1Nelfinavir 1Magnetic Resonance Spectroscopy 1Ipilimumab 1Gemcitabine 1Doxorubicin 1Dehydroepiandrosterone 1CTLA-4 Antigen 1Bupropion 1Blood Specimen Collection 1Bevacizumab 1Axitinib 11,2-diaminocyclohexaneplatinum II citrate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Vulvar Neoplasms × tivozanib × 90 days × Clear all
NCT05000294 2026-06-05

Atezolizumab Plus Tivozanib in Immunologically Cold Tumor Types

University of Florida

Phase 1/2 Recruiting
29 enrolled
BreastEndocrineGastrointestinalGenitourinaryGynecologicNETSarcoma

Bile Duct Neoplasms, Breast Neoplasms, Gallbladder Neoplasms, Ovarian Neoplasms, Prostatic Neoplasms, Sarcoma, Vulvar Neoplasms, Carcinoma, Neuroendocrine, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡